Additional work was carried out by Kalla et al. [14], who linked blood DNA methylation at TAP1 and two other genes to the need for IBD treatment escalation, while Joustra et al. [15] showed the potential of blood DNA methylation profiles (53 methylation probes) to predict the response of IBD to tofacitinib. The gene discussed is TAP1; the disease is inflammatory bowel disease.